Pharma Social Media and Updates
Pharma Social Media and Updates
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd https://t.co/ikQKjHjscU
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm https://t.co/FoT3i0xGcL
Genomic landscape of multiple myeloma and its precursor conditions [May 21, 2025] Jean-Baptiste Alberge et al. @IrenemGhobrial @NatureGenet https://t.co/DDWGRrpI4Y #mmsm #PrecisionMedicine #cagenome https://t.co/LY1MzFXSBN
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma [Jan 15, 2026] @hollyleeYJ et al. @NBahlis @NatureMedicine https://t.co/mz393mPMAq #mmsm #PrecisionMedicine #tcellrx THREAD: https://t.co/lNX9b7LsnR HT @AuclairDan https://t.co/2qih7LwP1c
Sen. Markey (D-Mass.) tells me outside the Capitol he doesn’t know who Vinay Prasad is and would need to be briefed by staff to respond to questions on the FDA
Consider this arc: peptides were around in niche communities, GLPs from Pharma then exploded, people realized they could take less or source them elsewhere, regulation enters & now gray & black market are going bye-bye & companies like HIMs &...
If big pharma sold to big 3 distributors at net prices rather than list prices, patients would save on average 40pct on their specialty and brand medications. This isn't hard. @BernieSanders @HawleyMO @SenTedCruz @SenateGOP @SenWarren @AOC https://t.co/COdRaMJPgq
The KRAS niche has been a deluge of new selective and pan/multi inhibitors. Now there are combos to watch out for – we may be making progress. Here are insights on 7 of them: https://t.co/F9HmM8A4ud https://t.co/IqWw6n2m3k
Another potential GLP-1 drug benefit seen in people with diabetes and brain metastases for improved survival; a retrospective study that needs further assessment but intriguing https://t.co/nZm3xEYQMH https://t.co/V76S7o1MJb
DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer [Feb 14, 2025] @KamyaSankar et al. @ReckampK Lung Cancer https://t.co/mXZ80zYke3 #lcsm #ImmunoOnc #PrecisionMedicine @TempusAI https://t.co/UJwZnw4qnc
Development & Validation of The Immune Profile Score (IPS), a Novel Multiomic Algorithmic Assay For Stratifying Outcomes in a Real-World Cohort of Pts w/ Adv Solid Cancer Tx'd w/ Immune Checkpoint Inhibitors [May 30, 2025] Zander etal @jitcancer https://t.co/rN5KIoVgPy #ImmunoOnc
Real-world clinical genomic analysis of Pts w/ BRAF mutated cancers identifies BRAF class II & III as a population of unmet medical need [3/7/22] Severson et al #ESMO2240P @TempusLabs https://t.co/s5PEBEczlv @Annals_OncologyDOI: https://t.co/c3wxWyUuX0 #PrecisionMedicine #caxtx
Mitochondria and Aging: Redox Balance Modulation as a New Approach to the Development of Innovative Geroprotectors (Fundamental and Applied Aspects) https://t.co/TcG9GjMVg7 @IJMS_MDPI https://t.co/gxCC9SsO7z
With $100M, Vima pursues an oral drug for movement disorders https://t.co/gLrhlYDMSy by @gwendolynawu #biotech #startups
Genomic Landscapes of Early-Onset vs Average-Onset Colorectal Cancer Populations [Feb 28, 2025] Storandt et al. @Cancers_MDPI https://t.co/as7Jolal12 #crcsm #PrecisionMedicine most significant difference b/w eoCRC & aoCRC was higher rates of BRAF mutation among Pts w/ aoCRC https://t.co/7qB4b3A1WK
Biotech Science at Less Than Zero | Ep. 955 https://t.co/4DXKsaKXdO [00:49] Biotech capital winter deep dive [01:17] Scientific leaps vs frozen markets [02:31] The 2020–2021 biotech bubble [03:42] Crossover funds fuel IPO surge [04:56] Interest rates freeze biotech funding [07:58] Negative enterprise value phenomenon [10:37] Why Big Pharma...
New nonprofit launches with at least $500 million to modernize scientific process for AI era https://t.co/yuypno6rVY via @ADeAngelis_bio
Correct. There will likely be no RCTs on BPC. Unless a new variant can perform better and be patented and Rx’d… and THATs happening.
The Role of Cellular Senescence and SASP in the Pathogenesis of Atherosclerosis and the Therapeutic Potential of Senolytic Strategies in Cardiovascular Diseases "Cellular senescence and SASP drive chronic inflammation and vascular dysfunction central to atherosclerosis pathogenesis, with senescent endothelial cells, VSMCs,...
Melatonin as a Guardian of Mitochondria: Mechanisms and Therapeutic Potential in Neurodegenerative Diseases https://t.co/kp4LZEbZzN https://t.co/boWzW7fcjM
Study shows nearly half of weight loss participants reduced alcohol use after starting anti-obesity medication (GLP-1 agonists, metformin, naltrexone). https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2827069 https://www.gatlan.com/ @GatlanHealth
Last fall the administration was talking about leucovorin as a potential treatment for large numbers of people with #autism. Today's approval suggests the evidence supports its use in a much smaller group of people, @rosebroderick_ reports. https://t.co/NlJR8KlaqP
BioNTech founders to step down and helm new mRNA startup https://t.co/yjvsVRQH2D by @Lilah_Alvarado $BNTX - 20%
Xenon hits a ‘home run’ in epilepsy; FDA restarts review of Duchenne cell therapy https://t.co/l40xYeW2Xh $XENE $CAPR + 15% $REGN $PFE $ABBV $GSK #biotech
$BBIO $ALNY moving higher on apparently good news re: Pfizer's tafamidis patent defense. If you have access to Umer Raffat's research, he has all the details.
🚨 @NPR spotlights our new JAMA Network Open study: One psilocybin dose + therapy gives 6X better odds of quitting smoking vs. nicotine patch + therapy. Game-changer for tobacco smoking addiction?
Predicting Alzheimer's disease up to 25 years in advance of any symptoms with the p-tau217 biomarker blood test, among 2,766 women mean age 70 https://t.co/aOActAUN27 https://t.co/Bxl2YZxnlf
DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma https://t.co/v39bOreJwu
Correction: I took down a post about Thursday's #VRBPAC meeting because it contained an error. #FDA has named 6 temporary voting members (not 2), which will bring the number for the meeting to 9. The temps are all former members....
$CAPR resubmission of the deramiocel application accepted by the FDA. New decision date: Aug. 22. https://t.co/mWSyyXg8di
How CRISPR works (in nature) and how it’s being leveraged as a tool for gene editing to cure and prevent diseases. Dr Alex Marson MD PhD of UCSF on the Huberman Lab podcast out now. https://t.co/fiL48JHxSL
$GSK is ostensibly the "sponsor" that won the approval but is once again saying it won't produce the drug.
Sticking with the science. I find that really impressive. BioNTech founders Uğur Şahin and Özlem Türeci are leaving the biotech they founded to start a new one. Maybe by the time they have something for the clinic, the FDA will...
PCSK9 in Vascular Aging and Age-Related Diseases Comprehensive summary of PCSK9's regulatory functions in vascular aging, highlighting potential therapeutic targets for combating age-related cardiovascular diseases. https://t.co/uo3PaSJLCb https://t.co/w8UZgIduPV
Actually he has it a bit backwards, those vaccinated with IPV can still acquire poliovirus and shed virus, but it prevents the virus from entering the bloodstream + protects almost 100% paralytic polio, just like the Covid vaccine protects 80-90%...
Vertex $VRTX says its drug successfully reduced marker of kidney disease in late-stage trial https://t.co/TbEkcHVYBB via @Jasonmmast
A new AI-driven workflow predicts the outcomes of asymmetric cross-coupling reactions, enabling chemists to efficiently identify optimal molecular structures while significantly reducing laboratory time and costs. drugdiscovery
Bristol Myers claims success in study of another next-gen blood cancer drug https://t.co/fqPbZ2Szv8 by @gwendolynawu $BMY
Check out this article I was apart of @MensHealthMag where I discuss currently approved FDA drugs that are potential geromedicines and our work on centenarians. https://t.co/e95XvnY9fb
What does it actually take to bring a biological product to market? For more than 20 years, Ingenza Ltd has helped teams avoid the most common failure points in synthetic biology. Freedom to operate issues. Low productivity. Fragile processes. Late CMC...
New FDA draft guidance outlines important streamlining of path to getting low-cost biosimilars to the market - could reduce cost of pharmacokinetic studies and allow ex-U.S. comparitor products to be used for proving biosimilarity to U.S.-licensed drugs https://t.co/ErjNOga0qo
Medicines plus healthy habits create outcomes that neither could achieve alone. A new @StanfordMed study published in JAMA shows digital lifestyle nudges may catalyze a critical first step toward behavior change for patients on GLP-1 medications. “Achieving your best health involves a...
UniQure leads genetic medicine biotech rally after news of Prasad’s exit https://t.co/zu1CtJfj29 by @realJacobBell $QURE $RGNX $ATRA $LXEO #GeneTherapy
I've covered most of the big controversies the FDA has faced over the past 25 years: Vioxx, drug-coated stents, and Aduhelm all spring to mind. In all of these cases, the FDA's advisory panel system, in which the agency calls together...
Just published @NatureMedicine A daily multivitamin (MVM) slowed epigenetic aging in a randomized trial after 2 years; effect was small (~2 months) and not seen with cocoa extract supplement (vitamin was Centrum Silver) https://t.co/snOMNsTzW7 https://t.co/a6MhMuRhJb
Would you like to hear an opinion on how the future of drug discovery will look like as foundation models become more capable in drug discovery tasks? Check out our dialogue and the first pilot with the foundation model genius @ramin_m_h...
Re: Prasad, from this morning's @statnews Readout newsletter: FDA Commissioner Marty Makary is in Miami this week speaking to health care investors attending a slew of broker conferences, noted Mizuho health care strategist Jared Holz. That should make for some...
The new Huberman Lab episode is out: Avoiding, Treating & Curing Cancer With the Immune System | Dr. Alex Marson 0:00 Alex Marson 2:21 Diseases & Current Biological Landscape; AI & Computational Tools 5:56 Immune System, Innate vs Adaptive Immune System 10:55 Thymus, T...
Not just replication, but triplication of the benefit of revving up cancer immunotherapy with FMT (Yes💩) https://t.co/rXyQdO74FJ
Two terrific #FDA related pieces by @lizzylawrence.bsky.social & @matthewherper.bsky.social. Matt's is a look at lessons to be drawn from Vinay Prasad's chaotic tenure; Lizzy's delves into the FDA's turning away from adcomms. https://t.co/gC5GNTiPm1 & https://t.co/ygvylHi0uz
